A Long-Term Complete Response (CR) of Avelumab in Patient (pt) with Advanced Merkel Cell Carcinoma (MCC) Abstract #1726

Introduction: MCC is a rare and aggressive cutaneous neuroendocrine cancer linked to exposure to the Merkel Polyomavirus (MCPyV). Cisplatin and VP16 chemo may be an effective treatment for metastatic MCC, but responses are often transient. The blockade of programmed death 1 (PD-1) immune inhibitory pathway by avelumab, an anti-PD-L1 checkpoint inhibitor, is being investigated in solid neoplasms. This strategy can also be of interest in MCC because these tumors often express PD-L1
Aim(s): to describe a case of advanced MCC in long term CR during immunotherapy with Avelumab
Materials and methods: A 60-year-old man was referred to our center in July 2015 for advanced MCC with nodes and skin lesions, after platinum-based chemo. A phase II, open-label, multicenter trial to investigate the activity and safety of avelumab in pts with advanced MCC was open for enrolment at our institution. The pt was eligible for treatment and started the treatment in August 2015
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: MD Sara Pusceddu

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2774 Metastatic Merkel Cell Carcinoma Associated Paraneoplastic Hyponatraemia: Response to Avelumab
Introduction: Merkel cell carcinoma (MCC) is rare, encompassing primary cutaneous neuroendocrine carcinoma.It has an aggressive natural history, and exhibits high response rates to radiotherapy & chemotherapy but often of short duration.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Elspeth Saunders
Authors: Saunders E, Demirel S, Kim S, Skelly R, ...
#2793 A Phase II, Open-Label, Multicenter Trial of Avelumab in Patients with Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive after First-line Chemotherapy (AVENEC)
Introduction: High grade Neuroendocrine Neoplasias (NEN) are rare tumors with a poor prognosis and no established second line therapy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: PD. Dr. Christian Fottner
#2796 Avelumab for Advanced Merkel Cell Carcinoma in the Netherlands; A Nationwide Survey
Introduction: Merkel cell carcinoma (MCC) is a rare, tumor of the skin associated with high recurrence rates and poor survival. Clinical trials have shown activity of checkpoint inhibitors targeting programmed death-(ligand)-1 (PD-(L)1). Avelumab is the only PD-L1 inhibitor that has been approved in the Netherlands for advanced/metastatic MCC (mMCC).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Sonja Levy
#2832 Lymph Node Merkel Cell Carcinoma without Primary: Long Term Survival
Introduction: Merkel cell carcinoma (MCC) is a rare aggressive cutaneous neuroendocrine carcinoma with a high rate of metastasis. Approximately 5% of MCC are found in the lymph nodes (LNs) without a primary tumor on the skin.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Mohammed Alaeddine Saidi
Authors: Saidi M A, Ghomari S, ...
#3070 Activity and Safety of Avelumab in Merkel Cell Carcinoma: Our Experience
Introduction: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin. The use of checkpoint inhibitors has shown good results in the treatment of advanced MCC. Avelumab is a PD-L1 inhibitor able to prevent the inactivation of the T lymphocytes. We report a serie of consecutive MCC cases treated with Avelumab in two centres
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Ivana Puliafito
Keywords: mcc, avelumab, activity, safety